# A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT03725852** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 68 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** GLPG1205
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03725852
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-27
- **Primary completion:** 2020-07-21
- **Final completion:** 2020-08-14
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03725852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03725852, "A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03725852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*